Navigation Links
United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
Date:2/19/2010

SILVER SPRING, Md., Feb. 19 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has withdrawn its Marketing Authorization Application (MAA) for Tyvaso (treprostinil sodium) 0.6 mg/ml nebuliser solution for the treatment of pulmonary arterial hypertension (PAH) in the European Union.

United Therapeutics submitted its MAA for Tyvaso to the European Medicines Agency (EMA) in December 2008.  The data included in the MAA is based upon clinical work performed from 2005 to 2007 by United Therapeutics' wholly-owned subsidiary Lung Rx, LLC.  The MAA was withdrawn following communication from the Committee for Medicinal Products for Human Use (CHMP) of the EMA citing a major objection.  The major objection noted that findings of non-compliance with good clinical practices (GCP) at two clinical sites would preclude a recommendation by the EMA for approval of the MAA for Tyvaso.

"Notwithstanding the fact that the EMA's major objection noted findings of non-compliance with good clinical practices, it is important to note that there were no major objections related to the safety or efficacy of Tyvaso," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer.

"Our revenue growth targets are unaffected by the withdrawal," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer.  "We have long based our growth targets on the estimated 30,000 diagnosed PAH patients in the US, including approximately 12,000 New York Heart Association Class III patients."

Conference Call

We will host a half-hour teleconference on Friday, February 19, 2010, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing (888) 211-7449, with international callers dialing (913) 312-0961. A rebroadcast of the teleconference will be available for one week by dialing (888) 203-1112, with international callers dialing (719) 457-0820 and using access code 3784360.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About Tyvaso

Tyvaso is an inhaled medicine used to treat PAH, a life-threatening disease that constricts the flow of blood through the pulmonary vasculature.  Tyvaso contains the same active ingredient (treprostinil) as Remodulin (treprostinil) Injection, which is also approved for the treatment of PAH.  Tyvaso is marketed by United Therapeutics and its wholly-owned subsidiary, Lung Rx, LLC.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements

Statements included in this press release concerning the impact of the GCP shortcomings identified by the EMA, the benefits of Tyvaso for patients, the number of diagnosed US PAH patients, and our revenue growth targets are "forward-looking statements" within the meaning of the safe harbor contained in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K, which could cause actual results to differ materially from anticipated results.  We are providing this information as of February 19, 2010, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.  [uthr-g]

Tyvaso and Remodulin are registered trademarks of United Therapeutics Corporation.

SOURCE United Therapeutics Corporation

Back to top

RELATED LINKS
http://www.unither.com

'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
2. United States continues to have highest level of health spending
3. United Medicorp, Inc.s Shareholders Approve All Proposals
4. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
5. Medical Services International Received Its First Order for Testing By Regulatory Agencies in the United States
6. Peoples United Financial CEO Has Surgery
7. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
8. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
9. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
10. Universal Health Care Coverage in the United States
11. Women Deliver Conference to Feature United Nations Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... To better understand the ... research award to examine gender differences in lung cancer. Today, the Lung Association announced ... Lung Cancer in Women Award, funded by the American Lung Association’s LUNG FORCE initiative, ...
(Date:5/24/2016)... ... , ... Jericho Project has named LaToya Williams-Belfort to the position of Chief ... and communications for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the ... at its roots. , “LaToya Williams-Belfort is joining Jericho at an exciting time ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The project ... services into a single site. , The new 2 story building houses the ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Boyd Industries, ... Concealed Delivery Unit® (CDU), a groundbreaking new product for pediatric dentistry , at ... Dentistry in San Antonio, TX May 26-29. The Concealed Delivery Unit keeps dental hand ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
(Date:5/23/2016)... YORK , May 23, 2016 ... Spectrometry Market Size, Share, Development, Growth and Demand ... (Hybrid, Single and Other), by Application (Drug Discovery ... by End Users (Pharmaceuticals, Life Science and Biotechnology, ... by P&S Market Research, the global mass ...
(Date:5/23/2016)... , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International Conference of ... under the distinguished patronage and presence of Sheikh Nahyan bin ... conference focused in Precision Medicine, which helps provide personalized medicine ...
Breaking Medicine Technology: